UK markets closed

Ultimovacs ASA (ULTI.OL)

Oslo - Oslo Delayed price. Currency in NOK
Add to watchlist
69.30-1.20 (-1.70%)
At close: 04:25PM CEST
Show:
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2021
31/12/2020
31/12/2019
31/12/2018
Total revenue
0
0
0
0
0
Operating expenses
Research development
93,482
96,735
64,660
35,528
16,957
Selling general and administrative
7,159
5,061
3,978
3,658
6,641
Total operating expenses
164,515
163,832
124,146
66,218
56,523
Operating income or loss
-164,515
-163,832
-124,146
-66,218
-56,523
Interest expense
2,707
333
240
263
133
Income before tax
-167,524
-164,722
-120,552
-61,166
-55,280
Income tax expense
0
0
0
0
0
Income from continuing operations
-167,524
-164,722
-120,552
-61,166
-55,280
Net income
-167,524
-164,722
-120,552
-61,166
-55,280
Net income available to common shareholders
-167,524
-164,722
-120,552
-61,166
-55,280
Basic EPS
-
-5.10
-4.00
-2.70
-3.45
Diluted EPS
-
-5.10
-4.00
-2.70
-3.45
Basic average shares
-
32,373
30,260
22,927
16,020
Diluted average shares
-
32,373
30,260
22,927
16,020
EBITDA
-
-161,686
-117,592
-58,840
-54,546